Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines.

Aurélien Vander Straeten | Morteza Sarmadi | John L Daristotle | Maria Kanelli | Lisa H Tostanoski | Joe Collins | Apurva Pardeshi | Jooli Han | Dhruv Varshney | Behnaz Eshaghi | Johnny Garcia | Timothy A Forster | Gary Li | Nandita Menon | Sydney L Pyon | Linzixuan Zhang | Catherine Jacob-Dolan | Olivia C Powers | Kevin Hall | Shahad K Alsaiari | Morris Wolf | Mark W Tibbitt | Robert Farra | Dan H Barouch | Robert Langer | Ana Jaklenec
Nature biotechnology | 2024

Decentralized manufacture of thermostable mRNA vaccines in a microneedle patch (MNP) format could enhance vaccine access in low-resource communities by eliminating the need for a cold chain and trained healthcare personnel. Here we describe an automated process for printing MNP Coronavirus Disease 2019 (COVID-19) mRNA vaccines in a standalone device. The vaccine ink is composed of lipid nanoparticles loaded with mRNA and a dissolvable polymer blend that was optimized for high bioactivity by screening formulations in vitro. We demonstrate that the resulting MNPs are shelf stable for at least 6 months at room temperature when assessed using a model mRNA construct. Vaccine loading efficiency and microneedle dissolution suggest that efficacious, microgram-scale doses of mRNA encapsulated in lipid nanoparticles could be delivered with a single patch. Immunizations in mice using manually produced MNPs with mRNA encoding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain stimulate long-term immune responses similar to those of intramuscular administration.

Pubmed ID: 37095347

Additional research tools detected in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NIAID NIH HHS, United States
    Id: P01 AI073748
  • Agency: NCI NIH HHS, United States
    Id: P30 CA014051

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Massachusetts Institute of Technology Swanson Biotechnology Center Nanotechnology Materials Core Facility (service resource)

RRID:SCR_018674

Provides instruments for materials and nanomaterials research and full service TEM and cryoTEM sample preparation and imaging. Conducts CLEM and cryoCLEM workflows utilizing cryoFluorescence, cryoSEM and cryoFIB with focus on bio samples.Provides equipment and expertise to work with nanomaterials for characterization and imaging purpose. Core imaging capabilities include high performance field emission transmission electron microscope equipped with STEM, EELS, EDS and cryo-imaging, high performance field emission scanning electron microscope and focused ion beam equipped with STEM and cryo-imaging, cryo-fluorescent confocal microscope for CLEM workflows, and atomic force microscope equipped with liquid cell. Instrumentation for material characterization includes high throughputdynamic light scattering, nanoparticle sizing and counting, and rheometry.

View all literature mentions